Our comprehensive and detailed analysis suggests that CASP4 may improve the prognosis of glioma patients mainly by affecting the immune microenvironment of the tumor, and the reduction of its expression level is an important guideline for improving the efficacy of immunotherapy and chemotherapy in glioma patients with different phenotypes and at different stages. The gene discussed is CASP4; the disease is central nervous system cancer.